UNSPSC 51241513: Brimonidine/timolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51241513 Brimonidine/timolol, a Commodity code, covers ophthalmic pharmaceutical products that state and local governments procure primarily through cooperative purchasing vehicles to support healthcare delivery across member jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent solicitation under this code — a Request for Proposal for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities, including Oregon. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, recruits manufacturers and suppliers who can deliver products meeting strict regulatory compliance standards, including certification of current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, along with comprehensive insurance coverage. Vendors must maintain contractual relationships with at least two of three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and provide pricing in formats including flat price, net price structures (NF30, NF60, NF90), or WAC-minus arrangements, with evaluation weighted heavily toward price competitiveness (75 percent) and administrative compliance (10 percent for fixed pricing, 5 percent each for EDI capability and fee structure agreement).

MMCAP's RFP, posted January 20, 2026, with a response deadline of March 26, 2026, is the only recent state or local opportunity identified under this code. The cooperative purchasing vehicle itself spans multiple states, reflecting typical multistate procurement architecture for pharmaceutical products. Awarded vendors will begin supplying authorized wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026; the contract term extends two years for new vendors with optional extensions at MMCAP's sole discretion, while incumbent responders' amendments align with existing expiration dates through June 30, 2028. Vendors should anticipate a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific award values or budget ranges are disclosed, and the solicitation does not identify set-aside designations limiting responses to particular business classifications or disadvantaged enterprises.